Natural killer cell lines in tumor immunotherapy. 2012

Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
Institute of Immunology, Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei 230027, China.

Natural killer (NK) cells are considered to be critical players in anticancer immunity. However, cancers are able to develop mechanisms to escape NK cell attack or to induce defective NK cells. Current NK cell-based cancer immunotherapy is aimed at overcoming NK cell paralysis through several potential approaches, including activating autologous NK cells, expanding allogeneic NK cells, usage of stable allogeneic NK cell lines and genetically modifying fresh NK cells or NK cell lines. The stable allogeneic NK cell line approach is more practical for quality-control and large-scale production. Additionally, genetically modifying NK cell lines by increasing their expression of cytokines and engineering chimeric tumor antigen receptors could improve their specificity and cytotoxicity. In this review, NK cells in tumor immunotherapy are discussed, and a list of therapeutic NK cell lines currently undergoing preclinical and clinical trials of several kinds of tumors are reviewed.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011946 Receptors, Antigen Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens. Antigen Receptors,Antigen Receptor,Receptor, Antigen
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016219 Immunotherapy, Adoptive Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314) Adoptive Cellular Immunotherapy,Adoptive Immunotherapy,CAR T-Cell Therapy,Cellular Immunotherapy, Adoptive,Chimeric Antigen Receptor Therapy,Immunotherapy, Adoptive Cellular,Adoptive Cellular Immunotherapies,Adoptive Immunotherapies,CAR T Cell Therapy,CAR T-Cell Therapies,Cellular Immunotherapies, Adoptive,Immunotherapies, Adoptive,Immunotherapies, Adoptive Cellular,T-Cell Therapies, CAR,T-Cell Therapy, CAR,Therapies, CAR T-Cell,Therapy, CAR T-Cell
D055612 Cytokine-Induced Killer Cells Mononuclear leukocytes that have been expanded in CELL CULTURE and activated with CYTOKINES such as INTERLEUKIN-2 to produce large numbers of highly cytotoxic cells. CIK Cells,Lymphocyte-Activated Killer Cell,Lymphocyte-Activated Killer Cells,CIK Cell,Cell, Lymphocyte-Activated Killer,Cells, Lymphocyte-Activated Killer,Cytokine Induced Killer Cells,Cytokine-Induced Killer Cell,Killer Cell, Cytokine-Induced,Killer Cell, Lymphocyte-Activated,Killer Cells, Cytokine-Induced,Killer Cells, Lymphocyte-Activated,Lymphocyte Activated Killer Cell,Lymphocyte Activated Killer Cells

Related Publications

Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
August 2023, Cancer biology & medicine,
Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
October 2022, Discover. Oncology,
Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
January 2016, Journal for immunotherapy of cancer,
Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
January 2014, Magnetic resonance insights,
Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
January 2020, Frontiers in immunology,
Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
January 2020, Advances in experimental medicine and biology,
Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
August 2012, Journal of vaccines & vaccination,
Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
December 2015, Current opinion in organ transplantation,
Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
February 2017, Nihon rinsho. Japanese journal of clinical medicine,
Min Cheng, and Jian Zhang, and Wen Jiang, and Yongyan Chen, and Zhigang Tian
November 2021, Small (Weinheim an der Bergstrasse, Germany),
Copied contents to your clipboard!